00380930552240 (باللغة العربية)
00380930552240 (باللغة العربية)
We had honor to accept at EmCell clinic Mr. R. attended by his parents.
The patient complains of the walking disorders, muscle weakness, inability to walk up and down stairs, to get up from the floor without help.
Examination by the neurologist
According to the parents, for half a year the condition of the boy has been satisfactory. Starting from March, some decrease in the quality of movement activity was observed. Within half a year the boy has gained 11 pounds (5 kg) in weight and 2–3 inches (7.5 cm) in height. The walking had improved - the expression of lordosis has diminished, he walks stepping with the full foot, can run. The strength in arms and legs has increased, hypotrophy of shoulder girdle muscles, and especially in pelvic girdle, has diminished. Arm reflexes D=S, knee - D=S, heel S=D; plantar reflexes are reported periodically. Gets up from the bed by himself. Sight is fixed, movements of eye apples are to a full range, convergence is good. The boy is in good spirits, attentive, does well in his studies. So, there is obvious positive progress in physical activity as well as growth and weight gain.
Diagnosis: Duchenne Muscular Dystrophy.
Lab tests (blood count, chemistry, routine urine test) were normal.
Recommendations: continue cell therapy.
Mr. R. received a course of cell therapy:
1st day of treatment. Administration of sample 3038I212 i.v. dropwise, 0.9 ml. administration of the sample 3038IM212 s/c in frontal abdomen, in two depots, 0.7 ml each. administration of sample 3038IE212, s/c in buttocks, in two depots, 1.0 ml each.
2nd day of treatment. Administration of sample 3038I212 i.v. dropwise, 0.9 ml. administration of sample 3038IM212 s/c in frontal abdomen, in two depots, 0,7 ml each. administration of sample 3038IE212, s/c in buttocks, in two depots, 0.8 ml each.
4th day of treatment. Administration of sample 3038A498 i.v. dropwise, 2.0 ml. administration of sample 3038AM498, s/c in frontal abdomen, in two depots, 1,1 ml each. administration of sample 3038IE406, s/c in buttocks, in two depots, 0.9 ml each.
5th day of treatment. Administration of sample 3038A498 i.v. dropwise, 1.0 ml. administration of sample 3038AE498, s/c in frontal abdomen, in two depots, 0.9 ml each.
7th day of treatment. administration of sample 3038AE498, s/c in frontal abdomen, in two depots, 1.2 ml each.
The cell suspension samples 30381212, 3038IM212, 3038IE212, 3038A498, 3038AM498, 3038IE406, and 3038AE498 are certified as follows:
|Bacterial sterility test||Negative|
|Test with cardiolipid antigen||Negative|
|Ami - HIV1/HIV2||Negative|
|Enzygnost Ami - HIV1/HIV2||Negative|
|Anti - HBc monoclonal||Negative|
|Anti - CMV/IgG+IgM||Negative|
|Anti - Rubella Virus/IgG||Negative|
Results of the treatment
During the course of treatment were observed the following positive changes: increase of the range of activity, good spirits.
Mr. R. is recommended:
1. Follow-up by the neurologist in the USA.
2. Diet rich in proteins (veal, fish, mushrooms, etc.).
3. Regular training in movement of legs and arms. Monthly measurements of weight and height.
4. Avoid infections.
5. Repeated course of cell therapy in 6–8 months. The exact timing of the visit is to be arranged in accordance with the changes of the patient's condition.